Taiwanese firm presents positive data on new long-acting interferon for rare cancer
The US branch of Taiwan’s PharmaEssentia (Taipei Exchange: 6446) has presented follow-up results from a trial of its orphan drug candidate Ropeginterferon alfa-2b at the ongoing American Society of Hematology (ASH) meeting in Atlanta, Georgia.
The data from the CONTI-PV trial, which is evaluating the therapy for patients with Polycythemia Vera, a cancer of the blood-building cells in the bone marrow, show positive results at the 24-month point.
At last year’s ASH, the company presented data from the 12 month point which showed non-inferiority to hydroxyurea in Complete Hematologic Response (CHR).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze